Francesca Bruce

4 days ago | insights.citeline.com | Francesca Bruce

Risk-Sharing Agreements & Greater Transparency In Pricing: What US Most Favored Nations Policy CouldA potential MFN drug pricing policy in the US could also lead to a greater push for collaborative action in the EU, such as joint procurement among the member states, says one European industry expert. A US MFN policy could mean new drug pricing agreements in France (Shutterstock)

5 days ago | insights.citeline.com | Francesca Bruce

US ‘Most Favored Nations’ Drug Pricing Policy Will Jeopardize Innovation In EuropeThe US MFN executive order is the latest in a series of concerning US developments that are contributing to uncertainty for the European pharmaceutical industry, according to France Biotech’s vice president, Alexandre Regniault. US pricing policies will hit pharmaceutical R&D (Shutterstock)

1 week ago | insights.citeline.com | Francesca Bruce

Could EU Collective Procurement Counter US Most Favored Nation Policy? Joint procurement, if used by member states to respond to potential pricing and access challenges caused by a US most favored nations pricing policy, would cause more uncertainty for pharmaceutical companies, warn industry representatives. Drug companies could think Germany Launch plans if the US were to reference Germany drug prices. (Shutterstock)

1 week ago | insights.citeline.com | Francesca Bruce

US Most Favored Nations Policy: Higher Drug Spending In Germany Is ‘Difficult To Imagine’ Executive summary: Germany’s federal health care decision-making body, the G-BA, tells the Pink Sheet that German drug prices are fair and speculation of price rises in the market due to the US MFN policy is fear mongering. A top German health care authority rejects the idea that Europe is free loading on US drug prices. (shutterstock)

2 weeks ago | insights.citeline.com | Francesca Bruce

US ‘Most Favored Nation’ Pricing Could be Game Changer for Drug Access In GermanyIn this first in a series of articles looking at the potential impact of the MFN drug pricing policy on European pharmaceutical markets, EUCOPE’s Alexander Natz tells the Pink Sheet why the US policy underscores the importance of confidential net pricing. Drug companies could think Germany Launch plans if the US were to reference Germany drug prices. (Shutterstock)